Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs.
GPCRs, which are signaling proteins in the human genome, are involved in virtually regulating all physiological processes.
The terms of the agreement include an up-front payment, research funding and success-based milestones.
ConfometRx CEO Tong Sun Kobilka said the company is delighted to work with UCB’s central nervous system research group to enhance the drug development activities.
"With over 20 years of experience working in the coupled receptor field and our unique technological approach, we believe that we can bring significant value to UCB’s novel drug development process," Kobilka added.
"We look forward to working closely with UCB’s R&D teams."